Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). (Q42222958)
Jump to navigation
Jump to search
scientific article published on 20 March 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). |
scientific article published on 20 March 2014 |
Statements
1 reference
Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). (English)
1 reference
1 reference
Laura Pérez-Martínez
Javier Aguilera-Lizarraga
Susana Rubio-Mediavilla
Judit Narro
20 March 2014
1 reference